Presenters
Professor of Internal Medicine
Michael Boehm, MD
Course Details
Hypertension affects a wide variety of patients and can be found across the cardiovascular continuum. During a webinar Professor Michael Boehm (Germany), he explained the importance of controlling hypertension, from mild-to-moderate hypertension, to those with high CV risk and those with kidney disease, as well as the role of inhibition of the renin-angiotensin system.
Estimated time of Completion: 39 mins and 31 secs.
CPD Points: 1 Point
PRC Program No: PROG-2024-82267
Hypertension Management Across the Full Patient Spectrum Course Outline
- Concept of global risk in cardio-renal metabolic (CRM) risk
- Main Groups of Indications Covered in Megatrials
- Involvement of AND II Different Pathomechanisms
- Avoidable cardiovascular events by baseline risk and extent of blood pressure lowering
- Hypertension – most prevalent risk factor
- Diabetes as typical example for combined CRM disease
- RAS inhibitors as comprehensive intervention
- SGLT2 inhibition as new kids on the block
- Synergistic effects
- Hypertension Prevalence by world region
- Causes of deaths worldwide attributed to increased blood pressure
- Blood-Pressure Thresholds at Which Antihypertensive Medications Should Be Used
- Core drug-treatment strategy for uncomplicated hypertension
- Fix combination pills: Improve adherence and persistence
- Risk, Blood Pressure and Diabetes in Hypertensives
- Symptomatic Heart Failure: Just the Tip of the Iceberg
- HOPE – First Evidence of RAS-Blockade in Global Protection
- Concept of Global Protection
- Telmisartan and ramipril in blood pressure and control: Powerful 24-h reduction
- Enhanced 24-hour Antihypertensive Efficacy
- Telmisartan in the only ARB indicated in CV high-risk patients – representing the majority of the patients typically seen in clinical practice
- Telmisartan has unique pharmacological profile in its class (ARB)
- Primary Outcome Telmisartan vs Ramipril
- Time to Permanent Discontinuation of Study Medication (ONTARGET)
- Main Groups of Indications Covered in Megatrials: Idea of RAS-Inhibition
- Majority of Trials with Oral Anti-Diabetics Show Neutral
- SGLT2 Inhibitors modulate several factors related to CV risk
PC-PH-105919 | July 2024